Profil
Gad Shani is the founder of Thulium Ltd.
He is currently a Professor-Emeritus at Ben-Gurion University of the Negev.
Aktive Positionen von Gad Shani
| Unternehmen | Position | Beginn |
|---|---|---|
Thulium Ltd.
 Thulium Ltd. Medical SpecialtiesHealth Technology Thulium Therapy is developing a new radioactive source for Brachytherapy, a cancer treatment modality were a radiation source is inserted into the tumor. The isotope, Thulium 170 (Tm170), is a radioactive variant of the stable metal Tm169. Although the concept of Brachytherapy is not new, much room remains for improvement in order to maximize the probability of completely eliminating a localized tumor while minimizing the radiation damage to the surrounding healthy tissue. | Gründer | 21.04.2010 |
| Ben-Gurion University of the Negev | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Thulium Ltd.
Thulium Ltd. Medical SpecialtiesHealth Technology Thulium Therapy is developing a new radioactive source for Brachytherapy, a cancer treatment modality were a radiation source is inserted into the tumor. The isotope, Thulium 170 (Tm170), is a radioactive variant of the stable metal Tm169. Although the concept of Brachytherapy is not new, much room remains for improvement in order to maximize the probability of completely eliminating a localized tumor while minimizing the radiation damage to the surrounding healthy tissue. | Health Technology |
